- Completed
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
Updated: May 24, 2022
1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Hematology Disease Topics & Pathways:
Biological, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Real World Evidence, Therapies, Registries, Lymphoid Malignancies, Infusion, Monoclonal Antibody Therapy
Saturday, December 11, 2021, 5:30 PM-7:30 PM
Conclusions:
In the meta-analyses, cilta-cel demonstrated a significant advantage over PCT in terms of OS and PFS, highlighting its potential as an effective therapy in patients with triple-class exposed RRMM.
COMY 22 - Session 15: Abstract communications
CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VERSUS PHYSICIAN’S CHOICE OF TREATMENT (PCT): A META-ANALYSIS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)